World Health Organization Sounds Warning Over Acute Lack of Obesity Medications
Less than a tenth of individuals who could benefit from GLP-1 drugs like Wegovy are able to get them, states the global health agency as it publishes its first guidance on the medications.
With more than one billion individuals worldwide now living with obesity, it is calling for increased and just availability to these injectable treatments.
According to forecasts, in excess of 2,000,000,000 will be obese by 2030 without intervention.
"Our latest guidelines recognises that obesity is a lifelong illness that can be managed with thorough and ongoing support," stated the agency's head Tedros Adhanom Ghebreyesus.
Significant expense, limited production capacity, and supply-chain constraints are major obstacles to universal availability to the treatments that can aid individuals in losing substantial body mass, notes the agency.
Weight-Loss Drug Shortage
Despite the current most favorable scenario, the supply of such drugs could only cover approximately 100 million people – less than 10% of the global need, per the WHO.
The recommendation encourages nations and manufacturers to widen availability, by strategies like voluntary licensing.
A patent on the active ingredient – the main ingredient of Novo Nordisk's Wegovy – is due to expire in a number of nations in 2026.
The Way Weight-Loss Injections Work
These medications imitate a biological compound to slow digestion, suppress the appetite and enhance satiety so users eat less.
People typically begin shedding pounds in the initial weeks of starting on the weekly injections.
Research points to users may regain a significant portion after a year of stopping the treatment, when their normal hunger return.
Being above a healthy weight increases your likelihood for experiencing diseases, including diabetes, cardiovascular issues, brain attack, and certain cancers.
Obesity concerns people in all nations and was associated with millions of deaths worldwide in 2024, according to the health agency.
